Literature DB >> 23910082

Genetic and epigenetic variations in iPSCs: potential causes and implications for application.

Gaoyang Liang1, Yi Zhang.   

Abstract

The ability to reprogram somatic cells to induced pluripotent stem cells (iPSCs) has revolutionized the field of regenerative medicine. However, recent studies on the genetic and epigenetic variations in iPSCs have raised concerns that these variations may compromise the utility of iPSCs. In this Perspective, we review the current understanding of genetic and epigenetic variations in iPSCs, trace their causes, discuss the implications of these variations for iPSC applications, and propose approaches to cope with these variations.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23910082      PMCID: PMC3760008          DOI: 10.1016/j.stem.2013.07.001

Source DB:  PubMed          Journal:  Cell Stem Cell        ISSN: 1875-9777            Impact factor:   24.633


  84 in total

1.  Derivation conditions impact X-inactivation status in female human induced pluripotent stem cells.

Authors:  Kiichiro Tomoda; Kazutoshi Takahashi; Karen Leung; Aki Okada; Megumi Narita; N Alice Yamada; Kirsten E Eilertson; Peter Tsang; Shiro Baba; Mark P White; Salma Sami; Deepak Srivastava; Bruce R Conklin; Barbara Panning; Shinya Yamanaka
Journal:  Cell Stem Cell       Date:  2012-07-06       Impact factor: 24.633

2.  Molecular signatures of human induced pluripotent stem cells highlight sex differences and cancer genes.

Authors:  Montserrat C Anguera; Ruslan Sadreyev; Zhaoqing Zhang; Attila Szanto; Bernhard Payer; Steven D Sheridan; Showming Kwok; Stephen J Haggarty; Mriganka Sur; Jason Alvarez; Alexander Gimelbrant; Maisam Mitalipova; James E Kirby; Jeannie T Lee
Journal:  Cell Stem Cell       Date:  2012-07-06       Impact factor: 24.633

3.  Identification of a specific reprogramming-associated epigenetic signature in human induced pluripotent stem cells.

Authors:  Sergio Ruiz; Dinh Diep; Athurva Gore; Athanasia D Panopoulos; Nuria Montserrat; Nongluk Plongthongkum; Sachin Kumar; Ho-Lim Fung; Alessandra Giorgetti; Josipa Bilic; Erika M Batchelder; Holm Zaehres; Natalia G Kan; Hans Robert Schöler; Mark Mercola; Kun Zhang; Juan Carlos Izpisua Belmonte
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-18       Impact factor: 11.205

4.  Background mutations in parental cells account for most of the genetic heterogeneity of induced pluripotent stem cells.

Authors:  Margaret A Young; David E Larson; Chiao-Wang Sun; Daniel R George; Li Ding; Christopher A Miller; Ling Lin; Kevin M Pawlik; Ken Chen; Xian Fan; Heather Schmidt; Joelle Kalicki-Veizer; Lisa L Cook; Gary W Swift; Ryan T Demeter; Michael C Wendl; Mark S Sands; Elaine R Mardis; Richard K Wilson; Tim M Townes; Timothy J Ley
Journal:  Cell Stem Cell       Date:  2012-04-26       Impact factor: 24.633

5.  Generating an iPSC bank for HLA-matched tissue transplantation based on known donor and recipient HLA types.

Authors:  Craig J Taylor; Sarah Peacock; Afzal N Chaudhry; J Andrew Bradley; Eleanor M Bolton
Journal:  Cell Stem Cell       Date:  2012-08-03       Impact factor: 24.633

6.  Erosion of dosage compensation impacts human iPSC disease modeling.

Authors:  Shila Mekhoubad; Christoph Bock; A Sophie de Boer; Evangelos Kiskinis; Alexander Meissner; Kevin Eggan
Journal:  Cell Stem Cell       Date:  2012-05-04       Impact factor: 24.633

7.  Trisomy correction in Down syndrome induced pluripotent stem cells.

Authors:  Li B Li; Kai-Hsin Chang; Pei-Rong Wang; Roli K Hirata; Thalia Papayannopoulou; David W Russell
Journal:  Cell Stem Cell       Date:  2012-10-18       Impact factor: 24.633

Review 8.  Epigenetic alterations in human pluripotent stem cells: a tale of two cultures.

Authors:  Anton Wutz
Journal:  Cell Stem Cell       Date:  2012-07-06       Impact factor: 24.633

9.  Somatic copy number mosaicism in human skin revealed by induced pluripotent stem cells.

Authors:  Alexej Abyzov; Jessica Mariani; Dean Palejev; Ying Zhang; Michael Seamus Haney; Livia Tomasini; Anthony F Ferrandino; Lior A Rosenberg Belmaker; Anna Szekely; Michael Wilson; Arif Kocabas; Nathaniel E Calixto; Elena L Grigorenko; Anita Huttner; Katarzyna Chawarska; Sherman Weissman; Alexander Eckehart Urban; Mark Gerstein; Flora M Vaccarino
Journal:  Nature       Date:  2012-11-18       Impact factor: 49.962

10.  Reprogramming to pluripotency can conceal somatic cell chromosomal instability.

Authors:  Masakazu Hamada; Liviu A Malureanu; Tobias Wijshake; Wei Zhou; Jan M van Deursen
Journal:  PLoS Genet       Date:  2012-08-30       Impact factor: 5.917

View more
  145 in total

1.  Automated, high-throughput derivation, characterization and differentiation of induced pluripotent stem cells.

Authors:  Daniel Paull; Ana Sevilla; Hongyan Zhou; Aana Kim Hahn; Hesed Kim; Christopher Napolitano; Alexander Tsankov; Linshan Shang; Katie Krumholz; Premlatha Jagadeesan; Chris M Woodard; Bruce Sun; Thierry Vilboux; Matthew Zimmer; Eliana Forero; Dorota N Moroziewicz; Hector Martinez; May Christine V Malicdan; Keren A Weiss; Lauren B Vensand; Carmen R Dusenberry; Hannah Polus; Karla Therese L Sy; David J Kahler; William A Gahl; Susan L Solomon; Stephen Chang; Alexander Meissner; Kevin Eggan; Scott A Noggle
Journal:  Nat Methods       Date:  2015-08-03       Impact factor: 28.547

2.  NF-κB activation impairs somatic cell reprogramming in ageing.

Authors:  Clara Soria-Valles; Fernando G Osorio; Ana Gutiérrez-Fernández; Alejandro De Los Angeles; Clara Bueno; Pablo Menéndez; José I Martín-Subero; George Q Daley; José M P Freije; Carlos López-Otín
Journal:  Nat Cell Biol       Date:  2015-07-27       Impact factor: 28.824

3.  Induced pluripotent stem cells for the treatment of recessive dystrophic epidermolysis bullosa.

Authors:  Stavros Spiliopoulos; Nikolaos Davanos
Journal:  Ann Transl Med       Date:  2015-12

4.  The distribution of genomic variations in human iPSCs is related to replication-timing reorganization during reprogramming.

Authors:  Junjie Lu; Hu Li; Ming Hu; Takayo Sasaki; Anna Baccei; David M Gilbert; Jun S Liu; James J Collins; Paul H Lerou
Journal:  Cell Rep       Date:  2014-03-27       Impact factor: 9.423

5.  Natural underlying mtDNA heteroplasmy as a potential source of intra-person hiPSC variability.

Authors:  Ester Perales-Clemente; Alexandra N Cook; Jared M Evans; Samantha Roellinger; Frank Secreto; Valentina Emmanuele; Devin Oglesbee; Vamsi K Mootha; Michio Hirano; Eric A Schon; Andre Terzic; Timothy J Nelson
Journal:  EMBO J       Date:  2016-07-19       Impact factor: 11.598

Review 6.  Manufacturing Cell Therapies Using Engineered Biomaterials.

Authors:  Amr A Abdeen; Krishanu Saha
Journal:  Trends Biotechnol       Date:  2017-07-12       Impact factor: 19.536

Review 7.  Toward pluripotency by reprogramming: mechanisms and application.

Authors:  Tao Wang; Stephen T Warren; Peng Jin
Journal:  Protein Cell       Date:  2013-11       Impact factor: 14.870

Review 8.  Mechanisms underlying the formation of induced pluripotent stem cells.

Authors:  Federico González; Danwei Huangfu
Journal:  Wiley Interdiscip Rev Dev Biol       Date:  2015-09-18       Impact factor: 5.814

Review 9.  Cell Therapy for Type 1 Diabetes: Current and Future Strategies.

Authors:  Yasaman Aghazadeh; Maria Cristina Nostro
Journal:  Curr Diab Rep       Date:  2017-06       Impact factor: 4.810

Review 10.  DLK1-DIO3 imprinted cluster in induced pluripotency: landscape in the mist.

Authors:  Leonidas Benetatos; George Vartholomatos; Eleftheria Hatzimichael
Journal:  Cell Mol Life Sci       Date:  2014-08-07       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.